Aegis Capital Corp. Announces the Hiring of a New Head of Equity Healthcare Research
New York, New York / ACCESSWIRE / November 9, 2022 / Aegis Capital Corp., - Aegis Capital Corp. (www.aegiscapcorp.com) a full-service wealth management, financial services and investment banking firm is pleased to announce Dr. David Bouchey has joined the firm as Head of Equity Healthcare Research
Dr. David Bouchey joins Aegis Capital as Head of Equity Healthcare Research. Prior to joining Aegis, Dr. Bouchey worked as a healthcare analyst at C.E. Unterberg, Towbin, LLC, Canaccord Adams Inc. and RBC Capital Markets Corp. focusing on small and mid-cap companies. Dr. Bouchey spent 16 years as a research scientist at different University labs before becoming a sell-side analyst, where he spent over 20 years identifying and evaluating emerging biotechnology and medical device companies. During his career, Dr. Bouchey analyzed hundreds of companies and over a hundred clinical trials, FDA applications and product launches. Dr. Bouchey was recognized for his research analysis by Institutional Investor Magazine, which designated him a Double Home Run Hitter, the only analyst to achieve that status since 1995. Dr. Bouchey also spent 8 years as an industry consultant and executive at Pharmacyclics and Capital Genomics, as well as the CEO of AntiSomaGen, a start-up biotechnology company. Dr. Bouchey holds a PhD in cell and molecular biology from the University of Virginia, an MBA in finance and monetary economics from the University of Kentucky, an MS in Virology from the University of Kentucky and a BS in Microbiology and Public Health from Michigan State University. He holds FINRA Series 7, 86 and 87 licenses.
Robert Eide Aegis’ CEO commented: “We are pleased Dr. Bouchey has joined Aegis’ research team. Dr. Bouchey’s extensive experience as a scientist as well as a research analyst gives him a unique perspective and ability to understand the science behind the companies, an essential element for successful research in such evolving areas as life sciences. Aegis is solidly committed to delivering our retail and institutional clients, along with our issuers, enlightening and insightful research.”
Michael Pata Aegis’ Head of Business Development commented: “Dr. Bouchey’s impressive track record of working in the healthcare space and his extensive leadership experience as an executive makes him an ideal choice for our firm. He has earned a reputation for insightful research that is thematic and actionable based on detailed analysis and modeling.”
About Aegis Capital Corporation
Aegis Capital Corporation “Aegis” has been in business for over 35 years catering to the needs of private clients, institutions and corporations. Aegis was founded in 1984 and offers its investment representatives a conflict free service platform and is able to provide a full range of products and services including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternatives, equity research, fixed income and special purpose vehicles. Aegis is able to provide quality service through its primary clearing relationship with RBC Clearing & Custody whose parent company, Royal Bank of Canada (NYSE:RY), is one of the world’s leading diversified financial services companies. Member: FINRA / SIPC.
Any questions contact:
Michael Pata, Head of Business Development
SOURCE: Aegis Capital Corp.